Aptose Biosciences Reschedules Special Meeting for Hanmi Acquisition

Aptose Biosciences Inc. announced the rescheduling of its special shareholder meeting, originally set for January 16, 2026, to a later date in January 2026. This meeting is to approve the company's continuance from the Canada Business Corporations Act to the Business Corporations Act (Alberta) and its subsequent acquisition by HS North America Ltd., a subsidiary of Hanmi Pharmaceutical Co. Ltd. The rescheduling is pending final clearance of the proxy statement from the U.S. Securities and Exchange Commission (SEC). The record date remains December 12, 2025. Aptose's board unanimously recommends voting in favor of the transaction. The company is a clinical-stage biotechnology firm focused on oncology, with its lead compound tuspetinib targeting acute myeloid leukemia.